ERK/MAPK signalling pathway and tumorigenesis
暂无分享,去创建一个
Ying Xu | Yan-Jun Guo | Wei-Wei Pan | Shengbing Liu | Z. Shen | Ying Xu | Ling-Ling Hu | Yan-Jun Guo | Wei-Wei Pan | Sheng-Bing Liu | Zhong-Fei Shen | Ling-Ling Hu | Sheng-Bing Liu
[1] J. Blenis,et al. The RSK family of kinases: emerging roles in cellular signalling , 2008, Nature Reviews Molecular Cell Biology.
[2] D. Morrison,et al. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. , 2003, Annual review of cell and developmental biology.
[3] Michiyuki Matsuda,et al. Divergent Dynamics and Functions of ERK MAP Kinase Signaling in Development, Homeostasis and Cancer: Lessons from Fluorescent Bioimaging , 2019, Cancers.
[4] Yoo Jin Jung,et al. The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.
[5] J. Lundeberg,et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.
[6] Honglin Luo,et al. Molecular Cloning of Mouse ERK5/BMK1 Splice Variants and Characterization of ERK5 Functional Domains* , 2001, The Journal of Biological Chemistry.
[7] Frank McCormick,et al. RAS Proteins and Their Regulators in Human Disease , 2017, Cell.
[8] Yuan Xu,et al. SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling. , 2018, Experimental and therapeutic medicine.
[9] D. Morrison,et al. Ras-Mediated Activation of the Raf Family Kinases. , 2019, Cold Spring Harbor perspectives in medicine.
[10] K. Patterson,et al. Dual-specificity phosphatases: critical regulators with diverse cellular targets. , 2009, The Biochemical journal.
[11] C. Der,et al. The role of wild type RAS isoforms in cancer. , 2016, Seminars in cell & developmental biology.
[12] Steffen Hauptmann,et al. Expression of mitogen‐activated protein kinase phosphatase‐1 (MKP‐1) in primary human ovarian carcinoma , 2002, International journal of cancer.
[13] E. Goldsmith,et al. Phosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation , 1998, Cell.
[14] M. Javan,et al. New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment , 2019, Front. Oncol..
[15] Roger J. Davis,et al. TNF and MAP kinase signalling pathways. , 2014, Seminars in immunology.
[16] H. Dohlman,et al. Regulation of large and small G proteins by ubiquitination , 2019, The Journal of Biological Chemistry.
[17] J. Ramos,et al. RSK isoforms in cancer cell invasion and metastasis. , 2013, Cancer research.
[18] M. Karin,et al. Mammalian MAP kinase signalling cascades , 2001, Nature.
[19] I. Berindan‐Neagoe,et al. A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer , 2019, Cancers.
[20] Chunli Shao,et al. The roles of MAPKs in disease , 2008, Cell Research.
[21] F. Dehghani,et al. The Cytoskeleton—A Complex Interacting Meshwork , 2019, Cells.
[22] E. Nishida,et al. Regulation of Nuclear Translocation of Extracellular Signal-Regulated Kinase 5 by Active Nuclear Import and Export Mechanisms , 2006, Molecular and Cellular Biology.
[23] R. Seger,et al. The ERK signaling cascade—Views from different subcellular compartments , 2009, BioFactors.
[24] P. LoRusso,et al. Clinical experience of MEK inhibitors in cancer therapy. , 2007, Biochimica et biophysica acta.
[25] R. Seger,et al. Protein-protein interactions in the regulation of the extracellular signal-regulated kinase , 2005, Molecular biotechnology.
[26] C. Flaitz,et al. PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma , 1999, British Journal of Cancer.
[27] P. Crespo,et al. Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway. , 2018, Trends in cancer.
[28] Y. Ho,et al. Vascular Endothelial Growth Factor-C Upregulates Cortactin and Promotes Metastasis of Esophageal Squamous Cell Carcinoma , 2014, Annals of Surgical Oncology.
[29] X. F. Zhang,et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. , 2001, Recent progress in hormone research.
[30] M. Nikiforova,et al. Molecular and Histopathologic Characteristics of Multifocal Papillary Thyroid Carcinoma , 2013, The American journal of surgical pathology.
[31] Nancy Y. Ip,et al. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF , 1991, Cell.
[32] Jing Zhao,et al. Role of big mitogen-activated protein kinase 1 (BMK1) / extracellular signal-regulated kinase 5 (ERK5) in the pathogenesis and progression of atherosclerosis. , 2012, Journal of pharmacological sciences.
[33] Jingwu Xie,et al. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas , 2009, Cell cycle.
[34] W. Park,et al. Colorectal tumors frequently express phosphorylated mitogen‐activated protein kinase , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[35] P. Leung,et al. Gonadotropin-releasing hormone activates mitogen-activated protein kinase in human ovarian and placental cells , 2000, Molecular and Cellular Endocrinology.
[36] Myungsun Shin,et al. Isoform-selective activity-based profiling of ERK signaling† †Electronic supplementary information (ESI) available: Experimental Methods and Supplementary Figures. See DOI: 10.1039/c8sc00043c , 2018, Chemical science.
[37] H. Namba,et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.
[38] Steven J. M. Jones,et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.
[39] Wei-Wei Pan,et al. DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway , 2018, Journal of Ovarian Research.
[40] A. Schulze,et al. Analysis of the transcriptional program induced by Raf in epithelial cells , 2001, Nature Genetics.
[41] F. McCormick,et al. Activation of c‐Raf‐1 by Ras and Src through different mechanisms: activation in vivo and in vitro , 1997, The EMBO journal.
[42] R. Roskoski. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. , 2019, Pharmacological research.
[43] Jesse S. Voss,et al. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] B. Su,et al. Dimerization through the Catalytic Domain Is Essential for MEKK2 Activation* , 2005, Journal of Biological Chemistry.
[45] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[46] M. Heikenwalder,et al. The role of polarisation of circulating tumour cells in cancer metastasis , 2019, Cellular and Molecular Life Sciences.
[47] I. Nagtegaal,et al. BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[48] R. Seger,et al. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. , 2011, Biochimica et biophysica acta.
[49] Y. Bang,et al. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. , 1998, Biochemical and biophysical research communications.
[50] Klaus Pantel,et al. Liquid Biopsy: Current Status and Future Perspectives , 2017, Oncology Research and Treatment.
[51] S. T. Eblen. Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes. , 2018, Advances in cancer research.
[52] W. Kolch. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. , 2000, The Biochemical journal.
[53] Donghui Wang,et al. Angiotensin II type 2 receptor–interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[54] E. Gelfand,et al. MEKK2 Associates with the Adapter Protein Lad/RIBP and Regulates the MEK5-BMK1/ERK5 Pathway* , 2001, The Journal of Biological Chemistry.
[55] Guohua Liu,et al. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. , 2017, Oncology letters.
[56] E. Nishida,et al. Activation of a C-terminal Transcriptional Activation Domain of ERK5 by Autophosphorylation* , 2007, Journal of Biological Chemistry.
[57] Y. Zou,et al. miR‑101 regulates the cell proliferation and apoptosis in diffuse large B‑cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway. , 2018, Oncology reports.
[58] San-Duk Yang,et al. Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer , 2017, Experimental &Molecular Medicine.
[59] C. Gialeli,et al. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.
[60] Qing-Yu He,et al. RNF128 Promotes Invasion and Metastasis Via the EGFR/MAPK/MMP-2 Pathway in Esophageal Squamous Cell Carcinoma , 2019, Cancers.
[61] B. Jiang,et al. P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. , 2010, Biochemical and biophysical research communications.
[62] P. Ladenson,et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.
[63] S. Keyse,et al. Dual-specificity MAP kinase phosphatases in health and disease☆ , 2019, Biochimica et biophysica acta. Molecular cell research.
[64] T. Miyase,et al. Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells. , 2003, Journal of agricultural and food chemistry.
[65] B. Evers,et al. Alterations of MAPK activities associated with intestinal cell differentiation. , 2001, Biochemical and biophysical research communications.
[66] A. Flanagan,et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.
[67] Hao Xu,et al. Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways. , 2007, Chinese medical journal.
[68] Frank McCormick,et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.
[69] L. Martiny,et al. The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells. , 2005, Experimental cell research.
[70] D. Bell,et al. Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.
[71] O. Kozawa,et al. Involvement of p38 MAP kinase in TGF‐β‐stimulated VEGF synthesis in aortic smooth muscle cells , 2001, Journal of cellular biochemistry.
[72] Ton Wang,et al. BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers , 2018, Drugs.
[73] P. Jänne,et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial , 2017, JAMA.
[74] Rony Seger,et al. The MEK/ERK cascade: from signaling specificity to diverse functions. , 2007, Biochimica et biophysica acta.
[75] G. Botti,et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] A. Ullrich,et al. The Unique C-terminal Tail of the Mitogen-activated Protein Kinase ERK5 Regulates Its Activation and Nuclear Shuttling* , 2005, Journal of Biological Chemistry.
[77] J C Reed,et al. Human intestinal epithelial cell survival: differentiation state-specific control mechanisms. , 2001, American journal of physiology. Cell physiology.
[78] R. Roskoski. ERK1/2 MAP kinases: structure, function, and regulation. , 2012, Pharmacological research.
[79] Oleksii S. Rukhlenko,et al. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. , 2018, Cell systems.
[80] D. Herr,et al. G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. , 2017, Biochimica et biophysica acta. Molecular cell research.
[81] R. Seger,et al. Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer , 2019, International journal of molecular sciences.
[82] W. Kolch,et al. Conferring specificity on the ubiquitous Raf/MEK signalling pathway , 2004, British Journal of Cancer.
[83] T. Ganesan,et al. Tumour angiogenesis—Origin of blood vessels , 2016, International journal of cancer.
[84] Su-qing Yang,et al. Long Noncoding RNA MIR4697HG Promotes Cell Growth and Metastasis in Human Ovarian Cancer , 2017, Analytical cellular pathology.
[85] Satoko Nishimoto,et al. MAPK signalling: ERK5 versus ERK1/2 , 2006, EMBO reports.
[86] S. Roy,et al. FGF9‐induced ovarian cancer cell invasion involves VEGF‐A/VEGFR2 augmentation by virtue of ETS1 upregulation and metabolic reprogramming , 2018, Journal of cellular biochemistry.
[87] Han-Wei Lin,et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. , 2012, The Biochemical journal.
[88] J. Avruch,et al. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.
[89] Masahito Watanabe,et al. Proliferative effects of γ‐aminobutyric acid on the gastric cancer cell line are associated with extracellular signal‐regulated kinase 1/2 activation , 2009, Journal of gastroenterology and hepatology.
[90] Alan R. Saltiel,et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.
[91] Rony Seger,et al. The ERK Cascade: Distinct Functions within Various Subcellular Organelles. , 2011, Genes & cancer.
[92] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[93] Zhong Yao and Rony Seger. The Molecular Mechanism of MAPK / ERK Inactivation , 2004 .
[94] M. Bogoyevitch,et al. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. , 2010, Biochimica et biophysica acta.
[95] R. Seger,et al. The dynamic subcellular localization of ERK: mechanisms of translocation and role in various organelles. , 2016, Current opinion in cell biology.
[96] David L. Brautigan,et al. The Specificity of Extracellular Signal-regulated Kinase 2 Dephosphorylation by Protein Phosphatases* , 2002, The Journal of Biological Chemistry.
[97] E. Wagner,et al. Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.
[98] Qing-Yu He,et al. RNF128 Promotes Invasion and Metastasis Via the EGFR/MAPK/MMP-2 Pathway in Esophageal Squamous Cell Carcinoma , 2019, Cancers.
[99] J. Kuriyan,et al. The Interdependent Activation of Son-of-Sevenless and Ras. , 2019, Cold Spring Harbor Perspectives in Medicine.
[100] J. Pouysségur,et al. Total ERK1/2 activity regulates cell proliferation , 2009, Cell cycle.
[101] M. Ladanyi,et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] Min Song,et al. Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors , 2018, BMC Systems Biology.
[103] Rony Seger,et al. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. , 2010, Methods in molecular biology.
[104] K. Ji,et al. Ras and Rap1: A tale of two GTPases. , 2019, Seminars in cancer biology.
[105] Jieun Park,et al. Ellipticine induces apoptosis in human endometrial cancer cells: the potential involvement of reactive oxygen species and mitogen-activated protein kinases. , 2011, Toxicology.
[106] W. Kolch,et al. Regulation of the MAPK pathway by raf kinase inhibitory protein. , 2014, Critical reviews in oncogenesis.
[107] I. Shih,et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.
[108] Herb Chen,et al. ZM336372, A Raf-1 Activator, Causes Suppression of Proliferation in a Human Hepatocellular Carcinoma Cell Line , 2008, Journal of Gastrointestinal Surgery.
[109] L. Hong,et al. MicroRNA‐508 suppresses epithelial‐mesenchymal transition, migration, and invasion of ovarian cancer cells through the MAPK1/ERK signaling pathway , 2018, Journal of cellular biochemistry.
[110] F. Zheng,et al. Emodin Increases Expression of Insulin-Like Growth Factor Binding Protein 1 through Activation of MEK/ERK/AMPKα and Interaction of PPARγ and Sp1 in Lung Cancer , 2017, Cellular Physiology and Biochemistry.
[111] F. Meric-Bernstam,et al. Targeting TRK family proteins in cancer , 2017, Pharmacology & therapeutics.
[112] Y. Li,et al. Sp1-CD147 positive feedback loop promotes the invasion ability of ovarian cancer. , 2015, Oncology reports.
[113] Y. Zimmer,et al. A Comparative Analysis of Individual RAS Mutations in Cancer Biology , 2019, Front. Oncol..
[114] R. Roskoski,et al. RAF protein-serine/threonine kinases: structure and regulation. , 2010, Biochemical and biophysical research communications.
[115] C. Marshall,et al. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.
[116] Jeanne Shen,et al. Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[117] R. Tapping,et al. MEKK3 Directly Regulates MEK5 Activity as Part of the Big Mitogen-activated Protein Kinase 1 (BMK1) Signaling Pathway* , 1999, The Journal of Biological Chemistry.
[118] A. Nebreda,et al. Roles of p38α mitogen‐activated protein kinase in mouse models of inflammatory diseases and cancer , 2015, The FEBS journal.
[119] H. Chung,et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis , 2000, Oncogene.
[120] W. Kolch. Coordinating ERK/MAPK signalling through scaffolds and inhibitors , 2005, Nature Reviews Molecular Cell Biology.
[121] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[122] C. V. Jongeneel,et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.
[123] M. Raffeld,et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. , 2012, Blood.